This Market Spotlight report covers the Zika Virus market, comprising key pipeline therapies, clinical trials, probability of success, and epidemiology.

Key Takeaways

• A total of 89 countries and territories have had documented evidence of autochthonous mosquito-borne transmission of Zika virus, including five of the six WHO regions, as of December 2021.
• The majority of industry-sponsored drugs in active clinical development for Zika virus are in Phase I, with a single product in Phase II.
• Therapies in development for Zika virus focus on the immune system, viral antigens, and RNA polymerase. Candidates comprise DNA vaccines such as GeneOne’s GLS-5700 and Inovio’s INO-A002; Moderna’s mRNA vaccine; Imutex’s AGS-v and AGS-v PLUS vaccines; Takeda’s TAK-426 vaccine; Emergent BioSolutions’ ZIKV-IG vaccine; and BioCryst’s galidesivir, a broad-spectrum antiviral drug.
• The overall likelihood of approval of a Phase I antiviral asset is 12.6%, and the average probability a drug advances from Phase III is 65.3%. Drugs, on average, take 8.4 years from Phase I to approval, compared to 8.9 years in the overall infectious disease space.
• All clinical trials for Zika virus have been in either Phase I or Phase II, with no Phase III trials to date.
• The US leads in terms of the number of Zika virus clinical trials globally.
• Inovio, GeneOne, Moderna, Emergent BioSolutions, and Merck & Co have two completed trials each in the Zika virus space. • Inovio, Moderna, and Sanofi lead industry sponsors with three clinical trials each for Zika virus.